

BAB VI

DAFTAR PUSTAKA

- Arizumi, T., Ueshima, K., Iwanishi, M., Minami, T., Chishina, H., Kono, M., *et al.*, 2017. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. *Liver Cancer* 2017;6:227–235.
[https://doi: 10.1159/000475777](https://doi.org/10.1159/000475777)
- Bai, DS., Zhang, C., Chen, P., Jin, SJ., Jiang, GQ., 2017. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. *Scientific Reports* Vol. 7: 12870.
[https://doi: 10.1038/s41598-017-12834-1](https://doi.org/10.1038/s41598-017-12834-1)
- Barghini, V., Donnini, D., Uzzau, A., Soardo, G., 2014. Signs and Symptoms of Hepatocellular Carcinoma - Future Outlook. *Intech open sign chapter* 10.
<http://dx.doi.org/10.5772/56162>
- Biolato, M., Gallusi, G., Iavarone, M., Cabibbo, G., Racco, S., De Santis, A., *et al.*, 2018. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. *Annals of Hepatology*, Vol. 17(1): 110-118.
[https://doi: 10.5604/01.3001.0010.7542](https://doi.org/10.5604/01.3001.0010.7542)
- Brar, G., Greten, TF., Graubard, BI., McNeel, TS., Petrick, JL., McGlynn, KA., 2020. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. *Hepatology Communications*, Vol. 4.
<https://doi.org/10.1002/hep4.1564>
- Choi, J., Lee, D., Shim, JH., Kim, KM., Lim, YS., Lee, YS., *et al.*, 2020. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. *PLOS ONE* 15(3).
<https://doi.org/10.1371/journal.pone.0229696>
- Dhanasekaran, R., Bandoh, S., Roberts, L. R., 2016. Molecular pathogenesis of Hepatocellular carcinoma and impact of therapeutic advances. *F1000Research* : 879. [https:// doi: 10.12688/f1000research.6946.1](https://doi.org/10.12688/f1000research.6946.1)
60(126). [https:// doi:10.5754/hge1299](https://doi.org/10.5754/hge1299)
- El-Fattah, MA., Aboelmagd, M., Elhamouly, M., 2017. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. *United European Gastroenterology Journal* 5(2).
[https://doi: 10.1177/2050640616659024](https://doi.org/10.1177/2050640616659024)
- PPHI, 2017. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Perhimpunan. Peneliti Hati Indonesia.
- PPHI, 2021. Konsensus Nasional Terapi Sistemik Karsinoma Sel Hati di Indonesia. Perhimpunan Peneliti Hati Indonesia.

- Hefaiiedh, R., Ennaifer, R., Romdhane, H., Nejma, HB., Arfa, N., Belhadj, N., 2013. Gender difference in patients with hepatocellular carcinoma. LA TUNISIE MEDICALE Vol. 91.
- Hsu, CY., Lee, YH., Hsia, CY., Huang, YH., Su, CW., Lin, HC., 2013. Performance Status in Patients With Hepatocellular Carcinoma: Determinants, Prognostic Impact, and Ability to Improve the Barcelona Clinic Liver Cancer System. HEPATOLOGY, Vol. 57, No. 1. <https://doi.org/10.1002/hep.25950>
- Hung, HS., Chao, Y., Chiou, YY., Li, CP., Lee, RC., Huo, TL., 2014. A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child–Pugh Scores of 5 or 6. Medicine Volume 93, No. 29. <https://doi.org/10.1097/MD.0000000000000348>
- Hung, Y. W., Lee, I. C., Chi, C. T., Lee, R. C., Liu, C. A., Chiu, N. C., *et al.*, 2021. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. Liver Cancer. <https://doi.org/10.1159/000517393>
- Huang A., Yang, X-R., Chung, W-Y., Dennison AR., Zhou, J., 2020. Targeted Therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 5:146. <https://doi.org/10.1038/s41392-020-00264-x>
- Izumi, R., Shimizu, K., Kiriya, M., Hashimoto, T., Urade, M., Yagi, M., 1992. Alpha-fetoprotein Production by Hepatocellular Carcinoma Is Prognostic of Poor Patient Survival. Journal of Surgical Oncology 49: 151-155. <https://doi.org/10.1002/jso.2930490305>.
- Kaibori, M., Yoshii, K., Yokota, I., Hasegawa, K., Nagashima, F., Kubo, S., 2017. Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma. Annals of Surgery Volume 20, No. 20. <https://doi.org/10.1097/SLA.0000000000002526>
- Kim, BS., Hayashi, PH., Kim, SH., Anghong, W., Srirattanapong, S., Woosley, JT., 2013. Outcomes of Patients with elevated Alpha Fetoprotein level and initial negative Findings at MR imaging. Radiology: Volume 268, No. 1. <https://doi.org/10.1148/radiol.13121314>
- Kudo, M., Han, K. H., Ye, S. L., Zhou, J., Huang, Y. H., Lin, S. M., *et al.*, 2020. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer, 9:245–260. <https://doi.org/10.1159/000507370>
- Lee, Y-T., Wang, JJ., Zhu, Y., Agopian, VG., Hsian- Rong Tseng, H-R., Yang, JD. 2021. Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. Clinical Liver Disease, Vol. 17, No 6. <https://doi.org/10.1002/cld.1075>
- Lei, J. Y., Wang, W. T., Yan, L. N., 2013. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: A single center analysis. World Journal of Gastroenterology 28; 19(36): 6077-83. <https://doi.org/10.3748/wjg.v19.i36.6077>

- Lin, CH., Lin, TJ., Hsieh, CF., Chen, T., Chen, KY., Huang, TC., *et al.*, 2014. Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization. *Digestive Medicine*; 1: 126-131. <https://doi.org/10.1016/j.aidm.2013.12.001>
- Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., *et al.*, 2021. Hepatocellular carcinoma. *Nature Review*.
<https://doi.org/10.1038/s41572-020-00240-3>
- Lopes, FdLM., Coelho, FF., Kruger, JAP., Fonseca, GM., Araujo, RLCd., Jeismann, VB., 2016. Influence of Hepatocellular Carcinoma Etiology in the survival After resection. *ABCD Arq Bras Cir Dig* ;29(2):105-108.
<https://doi.org/10.1590/0102-6720201600020010>
- María Reig, M., Forner, A., Avila, M. A., Ayuso, C., Minguez, B., Varela, M., *et al.*, 2021. Diagnosis and treatment of hepatocellular consensus carcinoma. Update Of the document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. *Med Clin (Barc)*. 156; 463.e1-e30. <https://doi.org/10.1016/j.medcli.2020.09.022>
- Markakis, G. E., Koulouris, A., Tampaki, M., Cholongitas, E., Deutsch, M., Papatheodoridis, G. V., *et al.*, 2022. The changing epidemiology of hepatocellular carcinoma in Greece. *Annals of Gastroenterology*; 35, 88-94
<https://doi.org/10.20524/aog.2021.0680>
- Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M.M., *et al.*, 2018. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*, Vol. 68, No. 2.
<https://doi.org/10.1002/hep.29913>
- Martino, M. D., Lai, Q., Lucatelli, P., Damato, E., Calabrese, A., Masci, G. M., *et al.*, 2021. Comparison of Up-to-seven criteria with Milan Criteria for liver transplantation in patients with HCC. *Trends in Transplant Volume* 14: 1-5. <https://doi.org/10.15761/TiT.1000300>
- McGlynn, K.A., Petrick, J. L., El-Serag, H. B., 2021. Epidemiology of Hepatocellular Carcinoma. *Hepatology* ; 73(Suppl 1): 4–13.
<https://doi.org/10.1002/hep.31288>
- Mehta, N., 2021. Liver Transplantation Criteria for Hepatocellular Carcinoma, including Posttransplant Management. *Clinical liver Disease*, vol 17, no 5.
<https://doi.org/10.1002/cld.1054>
- Miki, I., Murata, S., Uchiyama, F., Yasui, D., Ueda, T., Sugihara, F., *et al.*, 2017. Evaluation of the relationship between hepatocellular carcinoma location and Transarterial chemoembolization efficacy. *World J Gastroenterol* ; 23(35): 6437-6447. <https://doi.org/10.3748/wjg.v23.i35.6437>
- Müller, L., Stoeckl, F., Kunz, A. M., Hahn, F., Weinmann, A., Kloeckner, R., 2021. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. *Journal of Hepatocellular Carcinoma*: 8 403–419. <https://doi.org/10.2147/JHC.S285735>

- Müller, L., Hahn, F., Auer, T.A., Fehrenbach, U., Gebauer, B., Haubold, J., *et al.*, 2022. Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization : Head-to-Head Comparison of Current Scoring Systems. *Frontiers in Oncology*, Volume 12.
<https://doi.org/10.3389/fonc.2022.850454>
- Nishikawa, H., Kita, R., Kimura, T., Ohara, Y., Sakamoto, A., Saito, S., 2015. Clinical Implication of Performance Status in Patients with Hepatocellular Carcinoma Complicating with Cirrhosis. *Journal of Cancer* Vol. 6.
<https://doi.org/10.7150/jca.11212>
- Piscaglia, F., Terzi, E., Cucchetti, A., Trimarchi, C., Granito, A., Leoni, S., 2013. Treatment of hepatocellular carcinoma in Child-Pugh B patients. *Digestive and Liver Disease*, Vol. 45: 852–858. <http://doi.org/10.1016/j.dld.2013.03.002>
- Prince, D., Liu, K., Xu, W., Chen, M., Sun, J.Y., Lu, X.J., *et al.*, 2020. Management of patients with intermediate stage hepatocellular carcinoma. *Therapeutic Advances in Medical Oncology*, Vol. 12: 1–17.
<https://doi.org/10.1177/1758835920970840>
- Raoul, J.L., Forner, A., Bolondi, L., Cheung, T.T., Kloeckner, R., de Baere, T., 2019. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. *Cancer Treatment Reviews* 72; 28–36.
<https://doi.org/10.1016/j.ctrv.2018.11.002>
- Shimose, S., Kawaguchi, T., Iwamoto, H., Niizeki, T., Shirono, T., Tanaka, M., 2020. Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. *Oncology Letters*, 19: 2667-2676. <https://doi.org/10.3892/ol.2020.11399>
- Silk, T., Silk, W., Wu, J., 2022. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. *World J Gastroenterol* June 21; 28(23): 2561-2568.
<https://doi.org/10.3748/wjg.v28.i23.2561>
- Su, C.W., Lei, H.J., Chau, G.Y., Hung, H.H., Wu, J.C., Hsia, C.Y., 2012. The Effect of Age on the Long-term Prognosis of Patients With Hepatocellular Carcinoma After Resection Surgery. *ARCH SURG*, Vol. 147, No. 2.
<https://doi.org/10.1001/archsurg.2011.288>
- Tangkijvanich, P., Mahachai, V., Suwangool, P., Poovorawan, Y., 2004. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. *World Journal of Gastroenterology*, Vol. 10, No.11.
<https://doi.org/10.3748/wjg.v10.i11.1547>
- Tunissiolli, N. M., Castanhole-Nunes, M. M. U., Biselli-Chicote, P. M., Pavarino, E. C., da Silva, R. F., da Silva, R. D. C. M. A., Goloni-Bertollo, E. M., 2017. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. *Asian Pacific Journal of Cancer Prevention*, Vol 18; 863-872. <https://doi.org/10.22034/APJCP.2017.18.4.863>
- Villanueva, A., 2019. Hepatocellular Carcinoma. *The new england journal of medicine*; 380:1450-62. <https://doi.org/10.1056/NEJMra1713263>

- Wang, TC., An, TZ., Li, JX., Zhang, ZS., Xiao, YD., 2021. Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. *Frontiers in Molecular Biosciences*, Volume 8. . [https://doi: 10.3389/fmolb.2021.633590](https://doi:10.3389/fmolb.2021.633590)
- Yasui, Y., Tsuchiya, K., Kurosaki, M., Takeguchi, T., Takeguchi, Y., Okada, M., *et al.*, 2017. Up-to-seven criteria as a useful Predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after the initial conventional TACE: Predictive value of up-to-seven criteria. *Hepatology Research* 48(6). <https://doi:10.1111/hepr.13048>
- Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., *et al.*, 2020. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). *Liver Cancer* 2020;9:682–720. [https://doi: 10.1159/000509424](https://doi:10.1159/000509424)